These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35072888)

  • 61. Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers.
    Vaidya S; Ziegler D; Tanase AM; Malmqvist U; Kanniess F; Hederer B; Hosoe M
    Pulm Pharmacol Ther; 2021 Oct; 70():102019. PubMed ID: 33771722
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
    Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
    Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
    Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
    Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial.
    van Geffen WH; Carpaij OA; Westbroek LF; Seigers D; Niemeijer A; Vonk JM; Kerstjens HAM
    Respir Med; 2020 Sep; 171():106064. PubMed ID: 32917359
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
    Ficker JH; Rabe KF; Welte T
    Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone in Patients with COPD-A Cost-Effectiveness Analysis in the Czech Republic.
    Skoupa J; Kasak V; Klimes J; Valena T
    Value Health Reg Issues; 2018 Sep; 16():112-118. PubMed ID: 30539739
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
    Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
    Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Medication Adherence and Asthma Control with Once-Daily Indacaterol/Glycopyrronium/Mometasone Furoate Breezhaler Digital Companion: 90-Day Analysis from Germany.
    Woehrle H; Mastoridis P; Stempel D; Kaye L; Vuong V; Mezzi K
    Pulm Ther; 2023 Sep; 9(3):429-434. PubMed ID: 37120785
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
    Kerwin E; Ferguson GT; Sanjar S; Goodin T; Yadao A; Fogel R; Maitra S; Sen B; Ayers T; Banerji D
    Lung; 2017 Dec; 195(6):739-747. PubMed ID: 28993871
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program.
    Tsiligianni I; Mezzi K; Fucile S; Kostikas K; Shen S; Banerji D; Fogel R
    COPD; 2017 Aug; 14(4):375-381. PubMed ID: 28594587
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ten years of tiotropium: clinical impact and patient perspectives.
    Yohannes AM; Connolly MJ; Hanania NA
    Int J Chron Obstruct Pulmon Dis; 2013; 8():117-25. PubMed ID: 23515335
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
    Horita N; Kaneko T
    Int J Chron Obstruct Pulmon Dis; 2015; 10():813-22. PubMed ID: 25960646
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review.
    Ritondo BL; Puxeddu E; Calzetta L; Cazzola M; Rogliani P
    Expert Opin Pharmacother; 2021 Apr; 22(5):611-620. PubMed ID: 33131340
    [No Abstract]   [Full Text] [Related]  

  • 74. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment.
    Tervonen T; Martinez FJ; Hanania NA; Heidenreich S; Eudicone JM; Gilbert I
    Respir Med; 2021 Jan; 176():106278. PubMed ID: 33387985
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice.
    Tamm M; Richards DH; Beghé B; Fabbri L
    Respir Med; 2012 Dec; 106 Suppl 1():S9-19. PubMed ID: 23273165
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
    Petite SE
    Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.
    Vogelmeier CF; Chapman KR; Miravitlles M; Roche N; Vestbo J; Thach C; Banerji D; Fogel R; Patalano F; Olsson P; Kostikas K; Wedzicha JA
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1125-1134. PubMed ID: 29692607
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Study of the month : FLAME study in chronic obstructive pulmonary disease].
    Corhay JL
    Rev Med Liege; 2016 Sep; 71(9):400-406. PubMed ID: 28383836
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
    Bernstein D; Andersen L; Forth R; Jacques L; Yates L
    J Asthma; 2018 Sep; 55(9):984-993. PubMed ID: 28961020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.